In­te­gral Mol­e­c­u­lar's off-tar­get pro­tein bind­ing ar­ray nabs first spot in FDA pi­lot to speed new drug de­vel­op­ment tools

The FDA on Wednes­day of­fi­cial­ly kicked off a pi­lot pro­gram de­signed to ex­pand its qual­i­fi­ca­tion of out-of-scope drug de­vel­op­ment tools (DDTs) by se­lect­ing In­te­gral Mol­e­c­u­lar’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER